Sun Pharma announces results for investigational IL-23p19 inhibitor, tildrakizumab
Achieves primary end point in both phase-3 studies in patients with moderate-to-severe plaque Psoriasis
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.